ArticleMolecular biology reports2022
The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases.
Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Plant Immunometabolism: Metabolic Reprogramming Linking Developmental Signaling and Defense Metabolites.International journal of molecular sciences · 2026Review
- Multidimensional cfRNA response modeling identifies a 5-gene pair signature for high-robust pulmonary tuberculosis diagnosis.iScience · 2026Article
- Appraisal of CRISPR Technology as an Innovative Screening to Therapeutic Toolkit for Genetic Disorders.Molecular biotechnology · 2026Review
- RNA diagnostics and therapeutics: a comprehensive review.RNA biology · 2025Review
- A Review on the Current and Future State of Urinary Tract Infection Diagnostics.International journal of molecular sciences · 2025Review
- PlasmaInfectious diseases (London, England) · 2025Article
- Reinvigorating AMR resilience: leveraging CRISPR-Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security-a systematic review.Tropical medicine and health · 2025Review
- Recent developments and future directions in point-of-care next-generation CRISPR-based rapid diagnosis.Clinical and experimental medicine · 2025Review
- Overcoming the Delivery Challenges in CRISPR/Cas9 Gene Editing for Effective Cancer Treatment: A Review of Delivery Systems.International journal of medical sciences · 2025Review
- Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology.Frontiers in genome editing · 2025Review
- MultigeneThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2025Article
- A Concise Review of Major Challenges in the Vaccination, Diagnosis and Treatment of Novel Coronavirus Disease 2019.Archives of Razi Institute · 2024Review
- From COVID-19 to monkeypox: a novel predictive model for emerging infectious diseases.BioData mining · 2024Article
- The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer.Biomolecules · 2024Review
- Novel CRISPR/Cas13-based assay for detection of bovine coronavirus associated with severe diarrhea in calves.Tropical animal health and production · 2024Article
- Recent advances and challenges in plant viral diagnostics.Frontiers in plant science · 2024Review
- Challenges in Direct Detection of Flaviviruses: A Review.Pathogens (Basel, Switzerland) · 2023Review
- Visualizing the Nucleome Using the CRISPR-Cas9 System: From in vitro to in vivo.Biochemistry. Biokhimiia · 2023Review
- Detection of Tropical Diseases Caused by Mosquitoes Using CRISPR-Based Biosensors.Tropical medicine and infectious disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Emerging and relapsing infectious diseases pose a huge health threat to human health and a new challenge to global public health. Rapid, sensitive and simple diagnostic tools are keys to successful management of infectious patients and containment of disease transmission. In recent years, international research on Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-related proteins (Cas) has revolutionized our understanding of biology. The CRISPR-Cas system has the advantages of high specificity, high sensitivity, simple, rapid, low cost, and has begun to be used for molecular diagnosis and treatment of infectious diseases. In this paper, we described the biological principles, application fields and prospects of CRISPR-Cas system in the molecular diagnosis and treatment of infectious diseases, and compared it with existing molecular diagnosis methods, the advantages and disadvantages were summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.